244 related articles for article (PubMed ID: 34154596)
21. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
[TBL] [Abstract][Full Text] [Related]
22. A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
Yao L; Tang C; Feng W; Dai H
Med Sci Monit; 2022 Jun; 28():e937136. PubMed ID: 35718990
[TBL] [Abstract][Full Text] [Related]
23. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Pusceddu S; Ghidini M; Torchio M; Corti F; Tomasello G; Niger M; Prinzi N; Nichetti F; Coinu A; Di Bartolomeo M; Cabiddu M; Passalacqua R; de Braud F; Petrelli F
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30959763
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
26. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
[TBL] [Abstract][Full Text] [Related]
27. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
28. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Byun Y; Han Y; Kang JS; Choi YJ; Kim H; Kwon W; Kim SW; Oh DY; Lee SH; Ryu JK; Kim YT; Jang JY
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):416-425. PubMed ID: 31218836
[TBL] [Abstract][Full Text] [Related]
29. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06.
Morinaga S; Takita M; Yoshizawa A; Kamei K; Nakamori S; Ishihara S; Kuramochi H; Yokoyama Y; Uchiyama T; Murohisa G; Ishigaki M; Todaka A; Fukutomi A
Pancreas; 2020; 49(10):1372-1377. PubMed ID: 33122527
[TBL] [Abstract][Full Text] [Related]
30. Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine.
Di Costanzo F; Di Costanzo F; Antonuzzo L; Mazza E; Giommoni E
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672366
[TBL] [Abstract][Full Text] [Related]
31. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer.
Giuliani J; Bonetti A
Pancreatology; 2019 Mar; 19(2):325-330. PubMed ID: 30704852
[TBL] [Abstract][Full Text] [Related]
32. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
[TBL] [Abstract][Full Text] [Related]
33. A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Gao J; Logan KA; Nesbitt H; Callan B; McKaig T; Taylor M; Love M; McHale AP; Griffith DM; Callan JF
J Control Release; 2021 Oct; 338():358-366. PubMed ID: 34481018
[TBL] [Abstract][Full Text] [Related]
34. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
35. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
MacDonald K; Alrawashdh N; McBride A; Abraham I
Future Oncol; 2021 Nov; 17(33):4561-4570. PubMed ID: 34382416
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
37. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
38. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer.
Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
Pancreatology; 2020 Mar; 20(2):254-264. PubMed ID: 31866391
[TBL] [Abstract][Full Text] [Related]
39. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
40. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
